Effect of Montelukast 10 mg in Elderly Patients with Mild and Moderate Asthma Compared with Young Adults. Results of a Cohort Study.

BACKGROUND: The clinical characteristics and physio-pathogenic mechanisms of asthma in patients older than 60 years appear to differ from the behavior described for other age groups. Therefore, the effectiveness of medications for elderly patients with asthma should not be extrapolated from studies conducted on teenagers or young adults. OBJECTIVE: The study aimed to establish the clinical effect of montelukast 10 mg in elderly patients with mild and moderate asthma compared to its effect on young adults. METHOD: A prospective cohort study was conducted during 12 weeks of follow-up, which consecutively included the total population of adult patients attended by a group of 21 general practitioners, between July and December 2016. Young adults (18-59 years) and older adults were included (60 years or older) with mild or moderate asthma, which, according to the criteria of his treating physician, had been prescribed montelukast 10 mg/day. The variables of interest were: use of inhaled corticosteroids during the last month, use of inhaled beta-2 adrenergic agonists as a rescue in the last month, having attended the emergency service during the last month due to an asthma attack, presence of wheezing in the physical examination, the number of attacks in the last month and the number of days without symptoms in the last month. RESULTS: A total of 126 patients entered the cohort and 104 completed the follow-up, of which 29% were older adults. On admission, 65.4% of patients (68/104) had used rescue inhaled beta2 in the last month and had been using schemes with corticosteroids. After 12 weeks of follow-up, 58.1% (43/74) of the young adults required treatment schedules with corticosteroids, while in the elderly, only 36.7% of the patients (11/30) required this treatment scheme (p-value: 0.047). Regarding the use of rescue inhaled beta-2 at 12 weeks, 55% of young adults reported using them, compared to 33.3% of older adults (p-value: 0.041). CONCLUSION: In this cohort of patients, treated with montelukast 10 mg/day for 12 weeks, there was a reduction of broncho-obstructive symptoms and exacerbations of the disease. In older adults compared to young adults, a greater reduction in the use of beta2 agonists rescue medications and in the concomitant use of inhaled corticosteroid schemes was documented.

Molecularly targeted therapies for asthma: Current development, challenges and potential clinical translation.

Extensive research into the therapeutics of asthma has yielded numerous effective interventions over the past few decades. However, adverse effects and ineffectiveness of most of these medications especially in the management of steroid resistant severe asthma necessitate the development of better medications. Numerous drug targets with inherent airway smooth muscle tone modulatory role have been identified for asthma therapy. This article reviews the latest understanding of underlying molecular aetiology of asthma towards design and development of better antiasthma drugs. New drug candidates with their putative targets that have shown promising results in the preclinical and/or clinical trials are summarised. Examples of these interventions include restoration of Th1/Th2 balance by the use of newly developed immunomodulators such as toll-like receptor-9 activators (CYT003-QbG10 and QAX-935). Clinical trials revealed the safety and effectiveness of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonists such as OC0000459, BI-671800 and ARRY-502 in the restoration of Th1/Th2 balance. Regulation of cytokine activity by the use of newly developed biologics such as benralizumab, reslizumab, mepolizumab, lebrikizumab, tralokinumab, dupilumab and brodalumab are at the stage of clinical development. Transcription factors are potential targets for asthma therapy, for example SB010, a GATA-3 DNAzyme is at its early stage of clinical trial. Other candidates such as inhibitors of Rho kinases (Fasudil and Y-27632), phosphodiesterase inhibitors (GSK256066, CHF 6001, roflumilast, RPL 554) and proteinase of activated receptor-2 (ENMD-1068) are also discussed. Preclinical results of blockade of calcium sensing receptor by the use of calcilytics such as calcitriol abrogates cardinal signs of asthma. Nevertheless, successful translation of promising preclinical data into clinically viable interventions remains a major challenge to the development of novel anti-asthmatics.

Microbial biotransformation of beclomethasone dipropionate by Aspergillus niger

In the present research, the steroidal anti-asthmatic drug beclomethasone dipropionate was subjected to microbial biotransformation by Aspergillus niger. Beclomethasone dipropionate was transformed into various metabolites first time from microbial transformation. New drug metabolites produced can act as new potential drug molecules and can replace the old drugs in terms of safety, efficacy, and least resistance. They were purified by preparative thin layer chromatography technique, and their structures were elucidated using modern spectroscopic techniques, such as 13C NMR, 1H NMR, HMQC, HMQC, COSY, and NOESY, and mass spectrometry, such as EI-MS. Four metabolites were purified: (i) beclomethasone 17-monopropionate, (ii) beclomethasone 21-monopropionate, (iii) beclomethasone, and (iv) 9beta,11beta-epoxy-17,21-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 21-propionate.

Na pesquisa presente o fármaco esteróide antiasmático dipropionato de beclometasona foi submetido à biotransformação microbiana pelo Aspergillus niger. O dipropionato de beclometasona foi transformado, pela primeira vez, em metabólitos variados por biotransformação microbiana. Novos metabólitos do fármaco produzidos podem agir como novas moléculas potenciais e podem substituir os fármacos antigos em questão de segurança, eficácia e mínima resistência. Eles foram purificados por cromatografia em camada delgada preparativa e as suas estruturas foram elucidadas usando técnicas espectroscópicas modernas, como 13C NMR, 1H NMR; HMQC; HMQC; COSY, NOESY e espectrometria de massas, por exemplo, EI-MS. Purificaram-se quatro metabólitos, denominados (i) 17-monopropionato de beclometasona; (ii) 21-monopropionato de beclometasona: (iii) beclometasona e (iv) 21-propionato de 9beta,11beta-epoxi-17,21-diidroxi-16beta-metilpregna-1,4-dieno-3,20-diona.

Asma de difícil controle em pediatria: desafio presente e futuro / Hard-to-control asthma and pediatrics: current and future challenges

Objetivos: fazer revisão dos aspectos epidemiológicos, clínicos, propedêuticos e do manejo terapêutico da asma de difícil controle. Fonte dos dados: pesquisa não sistemática nas bases de dados Medline e LILACS. Síntese dos dados: a asma de difícil controle (ADC) constitui-se em síndrome definida na ausência de controle da asma com doses de budesonida, ou equivalente, iguais ou superiores a 800 ?g por dia. Apesar da simplicidade dessa definição clínica, o manejo propedêutico e terapêutico envolve multiplicidade de fatores e os pacientes devem ser acompanhados por pneumopediatra e equipe multidisciplinar em centros de referência. É necessário confirmar o diagnóstico de asma, avaliar diagnósticos alternativos e/ou fatores agravantes, verificar a adesão, a presença de causas psicossociais e estabelecer o fenótipo da asma a partir de marcadores inflamatórios (invasivos e não invasivos). As pesquisas revelam que os diferentes fenótipos requerem tratamentos específicos, entretanto, a aplicação na prática clínica desse conhecimento fenotípico ainda requer mais estudos. Conclusões: a asma de difícil controle em criança ou adolescente pode estar relacionada a múltiplas causas e à existência de diferentes subgrupos de ADC e com diferentes fisiopatologias de base.

Objectives: To review the epidemiological, clinical, propaedeutic aspects as well as the treatment of hard-to-control asthma. Source of data : Non-systematic research on Medline and LILACS databases. Data summary: Hard-to-control asthma (HCA) is a syndrome defined as the lack of asthma control despite daily doses of budesonide or equivalent that are equal to or higher than 800 ?g. This clinical definition may sound simple, but preliminary handling and treatment involve multiple factors and patients should be followed up by a pediatric pulmonologist and a multidisciplinary team at specialist care centers. It is necessary to confirm the diagnosis, to assess alternative diagnoses and/or aggravating factors, assess compliance and existence of psychosocial causes, and to define the asthma phenotype based on inflammatory markers (both invasive and non-invasive). Studies show that different phenotypes demand different treatments; however, further studies are needed to investigate the actual application of this knowledge in the clinical practice. Conclusions: Hard-to-control asthma in children or adolescents can be related to multiple causes and the existence of different HCA subgroups with different pathophysiological grounds